LIPOFLEX 1250 ML Emulsja do infuzji dożylnej

Ocena recepty online

Ocena recepty online

Lekarz przeanalizuje Twój przypadek i zdecyduje, czy wystawienie recepty jest medycznie uzasadnione.

Porozmawiaj z lekarzem o tym leku

Porozmawiaj z lekarzem o tym leku

Omów swoje objawy i opcje leczenia podczas szybkiej konsultacji online.

Lekarz
5.0(36)

Andrei Popov

Medycyna ogólnaMedycyna bólu7 lat doświadczenia

Dr Andrei Popov jest lekarzem rodzinnym ze specjalistycznym przygotowaniem w zakresie leczenia bólu przewlekłego. Prowadzi konsultacje wideo dla dorosłych w Hiszpanii i w całej Europie: zarówno jeśli od miesięcy zmagasz się z bólem, którego nikt nie potrafił dobrze wyjaśnić, jak i wtedy, gdy potrzebujesz rozwiązać problem zdrowotny bez czekania tygodniami na wizytę.

Jego podejście jest jasne: wysłuchać, uporządkować Twój przypadek i przedstawić praktyczny plan działania oparty na medycynie opartej na dowodach oraz dostosowany do Twojej historii medycznej i potrzeb.

Ból: w czym może pomóc

  •   Ból przewlekły (ponad 3 miesiące)
  •   Migrena i nawracające lub bardzo silne bóle głowy
  •   Ból szyi, odcinka lędźwiowego, pleców i stawów
  •   Ból pourazowy po urazach lub operacjach
  •   Ból pochodzenia neurologicznego: neuralgia, ból neuropatyczny, fibromialgia

Medycyna ogólna

  •   Częste infekcje dróg oddechowych (przeziębienie, grypa, uporczywy kaszel)
  •   Nadciśnienie, cukrzyca i zaburzenia metaboliczne
  •   Omówienie wyników badań laboratoryjnych oraz raportów MRI/CT (wyjaśnione prostym językiem)
  •   Medycyna profilaktyczna i monitorowanie zdrowia
  •   Druga opinia oraz dostosowanie leczenia (jeśli jest to klinicznie uzasadnione)

Jak wygląda konsultacja
 Każda sesja trwa do 30 minut. Omawiane są objawy, historia choroby, przyjmowane leki oraz dostarczone badania. Na zakończenie otrzymujesz jasny plan leczenia, kolejne kroki oraz wskazówki, kiedy warto zaplanować dalszą kontrolę. Jeśli zostaną wykryte sygnały alarmowe, lekarz jasno poinformuje, czy konieczna jest wizyta osobista lub pilna pomoc medyczna.

Umów wideokonsultację
zł365
Ta strona ma charakter informacyjny. Skonsultuj się z lekarzem, aby uzyskać indywidualną poradę. Jeśli objawy są poważne, zadzwoń pod numer alarmowy.
About the medicine

Jak stosować LIPOFLEX

Treść ulotki

  1. What is Lipoflex, AA 56 / G 144 and what is it used for
  2. What you need to know before using Lipoflex, AA 56 / G 144
  3. How to use Lipoflex, AA 56 / G 144
  4. Possible side effects
  5. How to store Lipoflex, AA 56 / G 144
  6. Package Contents and Other Information
  7. Possible side effects
  8. Contents of the pack and other information
  9. Possible side effects
  10. Package contents and other information
  11. What is Lipoflex, AA 56 / G 144 without electrolytes and what is it for
  12. What you need to know before using Lipoflex, AA 56 / G 144 without electrolytes
  13. How to use Lipoflex, AA 56 / G 144 without electrolytes
  14. Possible side effects
  15. How to store Lipoflex, AA 56 / G 144 without electrolytes
  16. Contents of the pack and other information

Lipoflex, AA 56 / G 144 emulsion for infusion
Read this leaflet carefully before you use this medicine as it contains important
information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others, even if their symptoms are the same as yours, as it could be harmful.
  • If you get any side effects, even those not listed in this leaflet, tell your doctor, pharmacist or nurse. See section 4.

Contents of this leaflet:

  • 1. What Lipoflex, AA 56 / G 144 is and what it is used for
  • 2. What you need to know before you use Lipoflex, AA 56 / G 144
  • 3. How to use Lipoflex, AA 56 / G 144
  • 4. Possible side effects
  • 5. How to store Lipoflex, AA 56 / G 144
  • 6. Contents of the pack and other information

1. What is Lipoflex, AA 56 / G 144 and what is it used for

Lipoflex, AA 56 / G 144 contains liquids and substances called amino acids, electrolytes and fatty acids, which are
essential for the body to grow or heal. It also contains calories in the form of carbohydrates and
fats.
Lipoflex, AA 56 / G 144 is administered when you are unable to feed yourself normally. This can
happen in many situations, for example after surgery, injuries or burns, or if you are unable to
absorb food in your stomach and intestines.

2. What you need to know before using Lipoflex, AA 56 / G 144

Do not use Lipoflex, AA 56 / G 144

  • if you are allergic to any of the active ingredients, to eggs, peanuts, soy or to any of the other components of this medicine (listed in section 6).
  • this medicine should not be administered to newborns, infants and children under two years of age.

In addition, do not use Lipoflex, AA 56 / G 144 if you suffer from any of the following conditions:

  • potentially life-threatening disorders of blood circulation, such as those that may occur in the event of collapse or shock
  • heart attack or stroke
  • severe impairment of blood coagulation, risk of bleeding (severe coagulopathy, worsening haemorrhagic diathesis)
  • blockage of blood vessels by blood clots or fat (embolism)
  • severe liver failure
  • impaired bile flow (intrahepatic cholestasis)
  • severe kidney failure without renal replacement therapy
  • imbalances in the salt content in the body
  • fluid deficiency or excess water in the body
  • water in the lungs (pulmonary edema)
  • severe heart failure
  • certain metabolic disorders, such as
    • too many lipids (fats) in the blood
    • congenital disorders of amino acid metabolism
    • levels of sugar in the blood that are too high and require more than 6 units of insulin per hour to keep under control
    • abnormalities of metabolism that may occur after surgery or injury
    • coma of unknown origin
    • insufficient oxygen supply to the tissues
    • too high levels of acids in the blood.

Warnings and precautions
Consult your doctor, pharmacist or nurse before using Lipoflex, AA 56 / G 144.
Tell your doctor if:

  • you have problems with your heart, liver or kidneys
  • you suffer from certain metabolic disorders such as diabetes, abnormal fat levels in the blood and imbalances in fluid and salt content in the body or alterations in acid-base balance.

You will be carefully monitored for early signs of an allergic reaction (such as fever, chills, rash or shortness of breath) when you receive this medicine.
Further checks and tests, such as various tests performed on blood samples, will be used to verify that
the body uses the administered nutrients correctly.
The nursing staff may also take appropriate measures to ensure an adequate supply of fluids and electrolytes
to your needs. In addition to Lipoflex, AA 56 / G 144 you may receive other nutrients (food)
to fully cover your needs.

Children
This medicine should not be administered to newborns, infants and children under two years of age.

Other medicines and Lipoflex, AA 56 / G 144
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take
any other medicine.
Lipoflex, AA 56 / G 144 can interact with other medicines. Tell your doctor, pharmacist or nurse if
you are taking or are being given any of the following medicines:

  • insulin
  • heparin
  • medicines that prevent inappropriate blood clotting, such as warfarin or other coumarin derivatives
  • medicines that promote urine flow (diuretics)
  • medicines used to treat high blood pressure (ACE inhibitors)
  • medicines used to treat high blood pressure or heart problems (angiotensin II receptor antagonists)
  • medicines used in organ transplantation, such as cyclosporine and tacrolimus
  • medicines used to treat inflammation (corticosteroids)
  • hormonal preparations that affect fluid balance (adrenocorticotropic hormone or ACTH)

Pregnancy and breastfeeding
If you are pregnant, suspect you are pregnant or are planning a pregnancy, or if you are breastfeeding with breast milk
ask your doctor or pharmacist for advice before taking this medicine. If you are pregnant, you will
receive this medicine only if your doctor or pharmacist considers it essential for recovery. No
data are available regarding the use of Lipoflex, AA 56 / G 144 in pregnant women.
Breastfeeding is not recommended for women receiving parenteral nutrition.

Driving and operating machinery
This medicine is normally administered to immobilized patients, e.g. in hospital or clinic,
who therefore do not drive or operate machinery. In any case, the medicine has no effects on the ability to
drive vehicles or operate machinery.

Doctor consultation

Nie jesteś pewien, czy ten lek jest odpowiedni dla ciebie?

Omów swoje objawy i leczenie z lekarzem online.

3. How to use Lipoflex, AA 56 / G 144

This medicine is administered via intravenous infusion (drip), i.e. through a small tube
inserted directly into a vein. The medicine is administered exclusively into one of the large veins
(central veins).
The doctor or pharmacist will determine the amount of medicine you need and the duration of treatment with
this medicine.

Use in children
This medicine should not be administered to newborns, infants and children under two years of age.

If you use more Lipoflex, AA 56 / G 144 than you should
If you have received an excessive amount of this medicine, you may suffer from the so-called “overload
syndrome” with the following symptoms:

  • excess fluid and electrolyte disturbances
  • fluid in the lungs (pulmonary edema)
  • loss of amino acids in the urine and disturbances in amino acid balance
  • vomiting, nausea
  • shivering
  • high blood sugar levels
  • glucose in the urine
  • fluid deficit
  • excessive blood concentration (hyperosmolarity)
  • reduction or loss of consciousness due to extremely high blood sugar levels
  • enlargement of the liver (hepatomegaly) with or without jaundice
  • enlargement of the spleen (splenomegaly)
  • fat deposition in internal organs
  • alterations in liver function parameters
  • low red blood cell count (anemia)
  • reduction in white blood cell count (leukopenia)
  • reduction in platelet count (thrombocytopenia)
  • increase in immature red blood cells (reticulocytosis)
  • breakdown of blood cells (hemolysis)
  • bleeding or tendency to bleed
  • blood clotting disorders (characterized by alterations in bleeding time, coagulation time, prothrombin time, etc.)
  • fever
  • high levels of fats in the blood
  • loss of consciousness

If any of these symptoms occur, the infusion must be stopped immediately.
If you have any doubts about the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
manifest.

The following side effects may be serious. If any of the following side effects occur, tell your doctor immediately, who will stop giving you this
medicine:

Rare (may affect up to 1 in 1,000 people):

  • allergic reactions, such as skin reactions, shortness of breath, swelling of the lips, mouth and throat, difficulty breathing

Other side effects include:
Uncommon (may affect up to 1 in 100 people):

  • nausea, vomiting, loss of appetite

Rare (may affect up to 1 in 1,000 users):

  • increased tendency of the blood to clot
  • bluish discoloration of the skin
  • shortness of breath
  • headache
  • hot flushes
  • redness of the skin (erythema)
  • sweating
  • chills
  • feeling of cold
  • elevated body temperature
  • drowsiness
  • chest, back, bone or lower back pain
  • decrease or increase in blood pressure

Very rare (may affect up to 1 in 10,000 people):

  • excessive levels of fats or sugars in the blood
  • high levels of acidic substances in the blood
  • An excess of lipids can lead to a lipid overload syndrome; for more information see “If you use more Lipoflex, AA 56 / G 144 than you should” in section 3. Symptoms usually disappear with discontinuation of the infusion.

Not known (frequency cannot be estimated from available data):

  • low white blood cell count (leukopenia)
  • low platelet count (thrombocytopenia)
  • impaired bile flow (cholestasis)

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse.
You can also report side effects directly through the national reporting system
at www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa ”. By reporting
side effects you can help provide more information on the safety of this medicine.

Medicine questions

Zacząłeś przyjmować lek i masz pytania?

Omów swoje objawy i leczenie z lekarzem online.

5. How to store Lipoflex, AA 56 / G 144

Keep this medicine out of sight and reach of children.
Do not store at a temperature above 25 °C.
Do not freeze. If accidental freezing occurs, discard the bag.
Keep the bag in the protective packaging to protect the medicine from light.
Do not use this medicine after the expiry date which is stated on the label. The expiry date refers
to the last day of that month.

6. Package Contents and Other Information

What Lipoflex, AA 56 / G 144 contains
The active ingredients contained in the ready-to-use mixture are:

from the upper compartment (glucose solution)t in
  • 1,000 ml
in 625 mlin
  • 1,250 ml
in 1,875 ml
I Glucose monohydrate equivalent to glucose158.4 g 144.0 g99.00 g 90.00 g198.0 g 180.0 g297.0 g 270.0 g
Dihydrate sodium phosphate2.496 g1.560 g3.120 g4.680 g
a Zinc acetate dihydrate7.024 mg4.390 mg8.780 mg13.17 mg
z from the intermediate compartment (lipid emulsion)in
  • 1,000 ml
in 625 mlin
  • 1,250 ml
in 1,875 ml
Refined soybean oil20.00 g12.50 g25.00 g37.50 g
n Medium chain triglycerides20.00 g12.50 g25.00 g37.50 g
g from the lower compartment (amino acid solution)in
  • 1,000 ml
in 625 mlin
  • 1,250 ml
in 1,875 ml
Isoleucine3.284 g2.053 g4.105 g6.158 g
A Leucine4.384 g2.740 g5.480 g8.220 g
Lysine hydrochloride equivalent to lysine3.980 g 3.186 g2.488 g 1.991 g4.975 g 3.982 g7.463 g 5.973 g
Methionine2.736 g1.710 g3.420 g5.130 g
Phenylalanine4.916 g3.073 g6.145 g9.218 g
Threonine2.540 g1.588 g3.175 g4.763 g
Tryptophan0.800 g0.500 g1.000 g1.500 g
Valine3.604 g2.253 g4.505 ga 6.758 g
Arginine3.780 g2.363 g4.725 g7.088 g
Histidine hydrochloride monohydrate equivalent to histidine2.368 g 1.753 g1.480 g 1.095 g2.960 g 2.191 gm 4.440 g 3.286 g
Alanine6.792 g4.245 g8.490 gr 12.73 g
Aspartic acid2.100 g1.313 g2.625 ga 3.938 g
Glutamic acid4.908 g3.068 g6.135 g9.203 g
Glycine2.312 g1.445 gF 2.890 g4.335 g
Proline4.760 g2.975 g5.950 g8.925 g
Serine4.200 g2.625 g5.250 g7.875 g
Sodium hydroxide1.171 g0.732 gl 1.464 g2.196 g
Sodium chloride0.378 g0.237 g0.473 g0.710 g
Sodium acetate trihydrate0.250 g0.157 ge 0.313 g0.470 g
Potassium acetate3.689 g2.306 g4.611 g6.917 g
Magnesium acetate tetrahydrate0.910 gd 0.569 g1.137 g1.706 g
Calcium chloride dihydrate0.623 g0.390 g0.779 g1.169 g
Electrolytesin
  • 1,000 ml
a in 625 mlin
  • 1,250 ml
in 1,875 ml
Sodium53.6 mmoln 33.5 mmol67 mmol100.5 mmol
Potassium37.6 mmol23.5 mmol47 mmol70.5 mmol
Magnesiuma 4.2 mmol2.65 mmol5.3 mmol7.95 mmol
Calciumi 4.2 mmol2.65 mmol5.3 mmol7.95 mmol
Zincl 0.03 mmol0.02 mmol0.04 mmol0.06 mmol
Chloride48 mmol30 mmol60 mmol90 mmol
Acetatea 48 mmol30 mmol60 mmol90 mmol
Phosphatet 16 mmol10 mmol20 mmol30 mmol
Amino acid content56.0 g35.0 g70.1 g105.1 g
Nitrogen content8 g5 g10 g15 g
a Carbohydrate content144 g90 g180 g270 g
Lipid content40 g25 g50 g75 g
z Energy supply in the form of lipids
  • 1,590 kJ (380 kcal)
995 kJ (240 kcal)
  • 1,990 kJ (475 kcal)
  • 2,985 kJ (715 kcal)
n Energy supply in the form of carbohydrates
  • 2,415 kJ (575 kcal)
  • 1,510 kJ (360 kcal)
  • 3,015 kJ (720 kcal)
  • 4,520 kJ (1,080 kcal)
e Energy supply in the form of amino acids940 kJ (225 kcal)585 kJ (140 kcal)
  • 1,170 kJ (280 kcal)
  • 1,755 kJ (420 kcal)
g Non-protein energy supply
  • 4,005 kJ (955 kcal)
  • 2,505 kJ (600 kcal)
  • 5,005 kJ(1. 195 kcal)
  • 7,505 kJ (1,795 kcal)
A Total energy supply
  • 4,945 kJ (1,180 kcal)
  • 3,090 kJ (740 kcal)
  • 6,175 kJ (1,475 kcal)
  • 9,260 kJ (2,215 kcal)

The other components are citric acid monohydrate (to adjust the pH), egg lecithin, glycerol, sodium oleate,
all-rac-alpha-tocopherol and water for injections.

Description of the appearance of Lipoflex, AA 56 / G 144 and package contents
The ready-to-use product is an emulsion for infusion, i.e. it is administered through a tube inserted
into a vein.
Lipoflex, AA 56 / G 144 is supplied in flexible multi-compartment bags containing:

  • 625 ml (250 ml of amino acid solution + 125 ml of lipid emulsion + 250 ml of glucose solution)
  • 1,250 ml (500 ml of amino acid solution + 250 ml of lipid emulsion + 500 ml of glucose solution)
  • 1,875 ml (750 ml of amino acid solution + 375 ml of lipid emulsion + 750 ml of glucose solution)
Osmolality
  • 2,115 mOsm m/kg
  • 2,115 mOsm m/kg
  • 2,115 mOsm m/kg
  • 2,115 mOsm m/kg
Theoretical osmolarity
  • 1,545 mOsm m/l
  • 1,545 mOsm m/l
  • 1,545 mOsm m/l
a
  • 1,545 mOsm m/l
pH5.0-6.05.0-6.05.0-6.05.0-6.0
Rectangular package with oxygen indicators and oxygen absorber highlighted by arrows and explanatory writingsInfusion bag divided into compartments labeled with glucose, fats, emulsion, amino acids and lower drug port

Figure A Figure B
Figure A: the multi-compartment bag is wrapped in a protective wrapper. Between the bag and the wrapper there is an
oxygen absorber and an oxygen indicator; the oxygen absorber sachet is made of inert material and
contains iron hydroxide.
Figure B: the upper compartment contains a glucose solution, the intermediate compartment contains
a lipid emulsion and the lower compartment contains an amino acid solution.
The glucose and amino acid solutions are clear and colorless or straw-yellow in color. The emulsion
lipid is milky white in appearance.
The upper and intermediate compartments can be connected to the lower compartment by opening the
intermediate welds.
The different container sizes are packaged in boxes containing five bags.
Packages: 5 x 625 ml, 5 x 1,250 ml and 5 x 1,875 ml
Not all packs may be marketed.

Marketing authorization holder and manufacturer

  • B. Braun Melsungen AG Carl-Braun-Str. 1 Postal address:34212 Melsungen, Germany 34209 Melsungen, Germany

Tel.: +49--5661-71-0
Fax: +49--5661-71-4567

This medicinal product is authorised in the Member States of the European Economic Area with the following
denominations:

Austria Nutriflex Lipid special B. Braun
Belgium Nutriflex Lipid special 56 g/l AA + 144 g/l G, emulsion for infusion
Denmark Lipoflex special
Finland Nutriflex Lipid 56/144/40
France LIPOFLEX LIPIDE G144/N8/E, emulsion for perfusion
Germany Nutriflex Lipid 56/144 special
Iceland Nutriflex Lipid 56/144 special
Italy Lipoflex, AA 56 / G 144
Luxembourg Nutriflex Lipid 56/144 special
Netherlands Nutriflex Lipid special, 56 g/l + 144 g/l emulsion for infusion
Norway Lipoflex special
Poland Lipoflex special
Spain Nutriflex Lipid 56/144 special Emulsión para perfusión
Sweden Nutriflex Lipid 56/144/40
United Kingdom Lipoflex special emulsion for infusion
______________________________________________________________________________
The following information is intended exclusively for physicians or healthcare professionals:
No special instructions for disposal.
Before use, parenteral nutrition products must be visually inspected for any damage, colour changes and emulsion instability.
Do not use damaged bags. The outer packaging, primary bag and weld between the compartments must be
intact. Use only if the amino acid and glucose solutions are clear and colourless to straw-yellow and if
the lipid emulsion is homogeneous and milky white in appearance. Do not use if the solutions contain
particles.
After mixing the three compartments, do not use if the emulsion shows colour changes or signs of
phase separation (oily droplets, oily layer). Immediately discontinue the infusion if
colour changes or signs of phase separation occur.
Before opening the outer packaging, check the colour of the oxygen indicator (see Figure A). Do not use if
the oxygen indicator is pink. Use only if the oxygen indicator is yellow.

Preparation of the emulsion by mixing
Strict adherence to aseptic procedures must be observed.
To open: tear the outer packaging starting from the designated incisions (Fig. 1). Remove the bag from the protective
packaging. Discard the outer packaging, oxygen indicator and oxygen absorber.
Visually inspect the primary bag for any leaks. Leaking bags must be
discarded, as sterility is not guaranteed in this case.

Hands opening and folding an aluminum pouch, arrows indicate the direction

To open and gradually mix the compartments, roll the bag with both hands, pressing on the
weld separating the upper compartment (glucose) from the lower compartment (amino acids) (Fig. 2a). Continue
to press until the weld separating the intermediate compartment (lipids) from the lower compartment is opened (Fig. 2b).
After removing the aluminum closure (Fig. 3), compatible additives can be added through the
port intended for adding medication (Fig. 4).

Hand grasping and opening a sealed transparent pouch in three successive steps with an arrow indicating the direction

Carefully mix the contents of the bag (Fig. 5) and visually inspect the mixture (Fig. 6). No
signs of phase separation of the emulsion should be visible.
The mixture is a homogeneous oil-in-water emulsion, milky white in appearance.

Preparation of the infusion
The emulsion must always be brought to room temperature before infusion.
Remove the aluminum film (Fig. 7) from the infusion port and connect the infusion set (Fig. 8).
Use a non-vented infusion set or close the air vent if a vented set is used. Hang the
bag on an IV pole (Fig. 9) and perform the infusion according to standard techniques.

Hands opening a sealed pouch, then extracting the contents and finally hanging a medical device on a vertical support

For single use only. The container and any unused residue must be discarded after use.
Do not reconnect partially used containers.
If filters are used, they must be permeable to lipids (pore size ≥1.2 µm).

Period of validity after removal of the protective packaging and mixing of the bag contents
The chemical and physicochemical stability in use of the mixture of amino acids, glucose and fats has been demonstrated for
7 days at 2-8°C and for 2 additional days at 25°C.

Period of validity after adding compatible additives
From a microbiological point of view, the product must be used immediately after the addition of additives.
If the product is not used immediately after the addition of additives, the user is responsible for the
timing and conditions of storage during use.
The emulsion must be used immediately after opening the container.
Lipoflex, AA 56 / G 144 should not be mixed with other medicinal products for which compatibility has not been
documented. Compatibility data for various additives (e.g. electrolytes, trace elements, vitamins) and the periods of
validity for these mixtures can be provided on request by the manufacturer.
Lipoflex, AA 56 / G 144 should not be administered simultaneously with a blood transfusion
in the same infusion set due to the risk of pseudoagglutination.

Duration of infusion of a single bag
The recommended infusion duration for a bag for parenteral nutrition is a maximum of 24 hours.

Lipoflex,AA32/G64 emulsion for infusion
Read this leaflet carefully before using this medicine as it contains important
information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed only for you. Do not pass it on to others, even if their symptoms are the same as yours, as it could be harmful.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. See section 4.

Contents of this leaflet:

  • 1. What is Lipoflex, AA32/G64 and what is it used for
  • 2. What you need to know before you use Lipoflex, AA32/G64
  • 3. How to use Lipoflex, AA32/G64
  • 4. Possible side effects
  • 5. How to store Lipoflex, AA32/G64
  • 6. Contents of the pack and other information
  • 1.What is Lipoflex,AA32/G64 and what is it used for

Lipoflex, AA32/G64 contains fluids and substances called amino acids, electrolytes and fatty acids, which are
essential for the body to grow or heal. It also contains calories in the form of carbohydrates and
fats.
Lipoflex, AA32/G64 is given to you when you are unable to feed yourself normally. This can
happen in many situations, for example after surgery, injuries or burns, or if you are unable to
absorb food in your stomach and intestines.

  • 2.What you need to know before you use Lipoflex,AA32/G64

Do not use Lipoflex,AA32/G64

  • if you are allergic to any of the ingredients in this medicine, to eggs, peanuts, soybeans or any of the other components of this medicine (listed in section 6).
  • This medicine must not be given to newborns, infants and children under two years of age.

Also, do not use Lipoflex, AA32/G64 if you suffer from any of the following conditions:

  • potentially life-threatening disorders of blood circulation, such as those that can occur in collapse or shock
  • heart attack or stroke
  • severe impairment of blood coagulation, risk of bleeding (severe coagulopathy, worsening haemorrhagic diathesis)
  • blockage of blood vessels by blood clots or fat (embolism)
  • severe liver failure
  • impaired bile flow (intrahepatic cholestasis)
  • severe kidney failure without renal replacement therapy
  • imbalances in the content of salts in the body
  • fluid deficiency or excess water in the body
  • water in the lungs (pulmonary edema)
  • severe heart failure
  • certain metabolic disorders, such as
    • too many lipids (fats) in the blood
    • congenital disorders of amino acid metabolism
    • very high blood sugar levels requiring more than 6 units of insulin per hour to control
    • abnormalities of metabolism that can occur after surgery or injury
    • coma of unknown origin
    • insufficient oxygen supply to the tissues
    • very high levels of acids in the blood.

Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Lipoflex, AA32/G64
Tell your doctor if:

  • you have problems with your heart, liver or kidneys
  • you suffer from certain metabolic disorders such as diabetes, abnormal fat levels in the blood and imbalances in fluid and salt content in the body or alterations in acid-base balance. You will be carefully monitored for early signs of an allergic reaction (such as fever, chills, rash or shortness of breath) when you receive this medicine.

Other checks and tests, such as various tests performed on blood samples, will be used to verify that
the body uses the nutrients supplied correctly.
The nursing staff may also take appropriate measures to ensure adequate fluid and electrolyte supply
to meet your needs. In addition to Lipoflex, AA32/G64 you may receive other nutrients (food) to
cover your entire needs.

Children
This medicine should not be given to newborns, infants and children under two years of age.

Other medicines and Lipoflex,AA32/G64
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take
any other medicines.
Lipoflex, AA32/G64 can interact with other medicines. Tell your doctor, pharmacist or nurse if you are
taking or are given any of the following medicines:

  • insulin
  • heparin
  • medicines that prevent inappropriate blood clotting, such as warfarin or other coumarin derivatives
  • medicines that promote urine flow (diuretics)
  • medicines used to treat high blood pressure (ACE inhibitors)
  • medicines used to treat high blood pressure or heart problems (angiotensin II receptor antagonists)
  • medicines used in organ transplantation, such as cyclosporine and tacrolimus
  • medicines used to treat inflammation (corticosteroids)
  • hormonal preparations that affect fluid balance (adrenocorticotropic hormone or ACTH)

Pregnancy and breastfeeding
If you are pregnant, suspect you are pregnant or are planning to become pregnant, or if you are breastfeeding,
ask your doctor or pharmacist for advice before taking this medicine. If you are pregnant, you will
receive this medicine only if your doctor or pharmacist considers it essential for recovery. There are
no data available on the use of Lipoflex, AA32/G64 in pregnant women.
Breastfeeding is not recommended for women receiving parenteral nutrition.

Driving and using machines
This medicine is normally given to immobilised patients, e.g. in hospital or clinic,
who therefore do not drive or use machines. In any case, the medicine has no effects on the ability to
drive vehicles or use machines.

  • 3.How to use Lipoflex,AA32/G64 This medicine is given by intravenous infusion (drip), i.e. through a small tube inserted directly into a vein. The medicine can be given in one of the small veins (peripheral veins) or large veins (central veins).

Your doctor or pharmacist will determine the amount of medicine you need and the duration of treatment with
this medicine.

Use in children
This medicine should not be given to newborns, infants and children under two years of age.

If you use more Lipoflex,AA32/G64 than you should
If you have received an excessive amount of this medicine, you may suffer from the so-called “overload syndrome” with the following symptoms:

  • excess fluid and electrolyte disturbances
  • fluid in the lungs (pulmonary edema)
  • loss of amino acids in the urine and disturbances of amino acid balance
  • vomiting, nausea
  • chills
  • high blood sugar levels
  • glucose in the urine
  • fluid deficit
  • excessive blood concentration (hyperosmolarity)
  • reduction or loss of consciousness due to extremely high blood sugar levels
  • enlargement of the liver (hepatomegaly) with or without jaundice
  • enlargement of the spleen (splenomegaly)
  • fat deposition in internal organs
  • alterations in liver function parameters
  • reductions in red blood cell count (anemia)
  • reduction in white blood cell count (leukopenia)
  • reduction in platelet count (thrombocytopenia)
  • increase in immature red blood cells (reticulocytosis)
  • rupture of blood cells (hemolysis)
  • bleeding or tendency to bleed
  • blood clotting disorders (characterized by alterations in bleeding time, coagulation time, prothrombin time, etc.)
  • fever
  • high levels of fats in the blood
  • loss of consciousness

If any of these symptoms occur, the infusion must be stopped immediately.
If you have any doubts about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
manifest.

The following side effects can be serious. If you experience any of the following side effects
inform your doctor immediately, who will stop administering this
medicine:

Rare (may affect up to 1 in 1,000 people):

  • allergic reactions, such as skin reactions, shortness of breath, swelling of the lips, mouth and throat, difficulty breathing

Other side effects include:
Common (may affect up to 1 in 10 people):

  • irritation or inflammation of the veins (phlebitis, thrombophlebitis)

Uncommon (may affect up to 1 in 100 people):

  • nausea, vomiting, loss of appetite

Rare (may affect up to 1 in 1,000 people):

  • increased tendency of the blood to clot
  • bluish discoloration of the skin
  • shortness of breath
  • headache
  • hot flushes
  • redness of the skin (erythema)
  • sweating
  • shivering
  • feeling cold
  • elevated body temperature
  • drowsiness
  • pain in the chest, back, bones or lower back
  • decrease or increase in blood pressure

Very rare (may affect up to 1 in 10,000 people):

  • excessive levels of fats or sugars in the blood
  • high levels of acidic substances in the blood
  • An excess of lipids can lead to a lipid overload syndrome; for more information see “If you use more Lipoflex, AA32/G64 than you should” in section 3. Symptoms generally disappear with discontinuation of the infusion. Not known (frequency cannot be estimated from available data):
  • decrease in the number of white blood cells (leukopenia)
  • decrease in the number of platelets in the blood (thrombocytopenia)
  • impaired bile flow (cholestasis)

Reporting of side effects
If you get any side effects, even those not listed in this leaflet, tell your
doctor, pharmacist or nurse.
You can also report side effects directly through the national reporting system
at www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa ”.
By reporting side effects you can help provide more information on the safety of this
medicine.

  • 5.How to store Lipoflex,AA32/G64

Keep this medicine out of the sight and reach of children.
Do not store above 25 °C.
Do not freeze. If accidental freezing occurs, discard the bag.
Keep the bag in the protective packaging to protect the medicine from light.
Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to
the last day of that month.

6. Contents of the pack and other information

What Lipoflex,AA32/G64 contains,
The active ingredients contained in the ready-to-use mixture are:

a from the upper compartment i (glucose solution)in
  • 1,000 ml
in 1,250 mlin 1,875 mlin 2,500 ml
z Glucose monohydrate equivalent to glucose70.40 g 64.00 g88.00 g 80.00 g132.0 g176.0 g
120.0 g160.0 g
Disodium hydrogen phosphate dihydrate0.936 g1.170 g1.755 g2.340 g
n Zinc acetate dihydrate5.280 mg6.600 mg9.900 mg13.20 mg
e from the intermediate compartment (lipid emulsion)in
  • 1,000 ml
in 1,250 mlin 1,875 mlin 2,500 ml
g Refined soybean oil20.00 g25.00 g37.50 g50.00 g
Medium chain triglycerides20.00 g25.00 g37.50 g50.00 g
from the lower compartment (amino acid solution)in
  • 1,000 ml
in 1,250 mlin 1,875 mlin 2,500 ml
Isoleucine1.872 g2.340 g3.510 g4.680 g
Leucine2.504 g3.130 g4.695 g6.260 g
Lysine hydrochloride equivalent to lysine2.272 g 1.818 g2.840 g 2.273 g4.260 g 3.410 gc 5.680 g 4.546 g
Methionine1.568 g1.960 g2.940 ga 3.920 g
Phenylalanine2.808 g3.510 g5.265 g7.020 g
Threonine1.456 g1.820 g2.730 gm 3.640 g
Tryptophan0.456 g0.570 g0.855 g1.140 g
Valine2.080 g2.600 g3.900 g5.200 g
Arginine2.160 g2.700 g4.050 gr 5.400 g
Histidine hydrochloride monohydrate equivalent to histidine1.352 g 1.000 g1.690 g 1.251 ga 2.535 g 1.876 g3.380 g 2.502 g
Alanine3.880 g4.850 gF 7.275 g9.700 g
Aspartic acid1.200 g1.500 g2.250 g3.000 g
Glutamic acid2.800 g3.500 g5.250 g7.000 g
Glycine1.320 g1.650 gl 2.475 g3.300 g
Proline2.720 g3.400 g5.100 g6.800 g
Serine2.400 g3.000 ge 4.500 g6.000 g
Sodium hydroxide0.640 g0.800 g1.200 g1.600 g
Sodium chloride0.865 gd 1.081 g1.622 g2.162 g
Sodium acetate trihydrate0.435 g0.544 g0.816 g1.088 g
Potassium acetate2.354 g2.943 g4.415 g5.886 g
Magnesium acetate tetrahydrate0.515 ga 0.644 g0.966 g1.288 g
Calcium chloride dihydrate0.353 g0.441 g0.662 g0.882 g
Electrolytesi in
  • 1,000 ml
a in 1,250 mlin 1,875 mlin 2,500 ml
Sodiuml 40 mmol50 mmol75 mmol100 mmol
Potassium24 mmol30 mmol45 mmol60 mmol
Magnesiuma 2.4 mmol3.0 mmol4.5 mmol6.0 mmol
Calciumt 2.4 mmol3.0 mmol4.5 mmol6.0 mmol
ZincI 0.024 mm ol0.03 mmol0.045 mmol0.06 mmol
Chloride38 mmol48 mmol72 mmol96 mmol
a Acetate32 mmol40 mmol60 mmol80 mmol
Phosphate6.0 mmol7.5 mmol11.25 mmol15.0 mmol
z Amino acid content32 g40 g60 g80 g
Nitrogen content4.6 g5.7 g8.6 g11.4 g
n Carbohydrate content64 g80 g120 g160 g
Lipid content40 g50 g75 g100 g
g Energy supply in the form of lipids
  • 1,590 kJ (380 kcal)
  • 1,990 kJ (475 kcal)
  • 2,985 kJ (715 kcal)
  • 3,980 kJ (950 kcal)
Energy supply in the form of carbohydrates
  • 1,075 kJ (255 kcal)
  • 1,340 kJ (320 kcal)
  • 2,010 kJ (480 kcal)
  • 2,680 kJ (640 kcal)
A Energy supply in the form of amino acids535 kJ (130 kcal)670 kJ (160 kcal)
  • 1,005 kJ (240 kcal)
  • 1,340 kJ (320 kcal)
Non-protein energy supply
  • 2,665 kJ
  • 3,330 kJ
  • 4,995 kJ
  • 6,660 kJ
(635 kcal)(795 kcal)(1,195 kcal)(1,590 kcal)
Total energy supply
  • 3,200 kJ (765 kcal)
  • 4,000 kJ (955 kcal)
  • 6,000 kJ (1,435 kcal)
c
  • 8,000 kJ (1,910 kcal)
Osmolality950 mOsm /kg950 mOsm/kg950 mOsm/kg950 mOsm/kg
Theoretical osmolarity840 mOsm /l840 mOsm/l840 mOsm/lm 840 mOsm/l
pH5.0-6.05.0-6.05.0-6.0r 5.0-6.0

The other components are citric acid monohydrate (to adjust the pH), egg lecithin, glycerol, sodium oleate,
all-rac-alpha-tocopherol and water for injections.

Description of the appearance of Lipoflex,AA32/G64 and contents of the pack
The ready-to-use product is an emulsion for infusion, i.e. it is administered through a tube inserted
into a vein.
Lipoflex, AA32/G64 is supplied in flexible multi-compartment bags containing:

  • 1,250 ml (500 ml of amino acid solution + 250 ml of lipid emulsion + 500 ml of glucose solution)
  • 1,875 ml (750 ml of amino acid solution + 375 ml of lipid emulsion + 750 ml of glucose solution)
  • 2,500 ml (1,000 ml of amino acid solution + 500 ml of lipid emulsion + 1,000 ml of glucose solution)
Rectangular packaging with oxygen indicators, oxygen absorber, tear notches and overcover highlighted by arrowsInfusion bag divided into four sections labeled: glucose, lipids, emulsion and amino acid solution with infusion port and medication
Packaging

Figure A Figure B
Figure A: the multi-compartment bag is wrapped in a protective packaging. Between the bag and the packaging there are an
oxygen absorber and an oxygen indicator; the oxygen absorber bag is made of inert material and
contains iron hydroxide.
Figure B: the upper compartment contains a glucose solution, the intermediate compartment contains
a lipid emulsion and the lower compartment contains an amino acid solution.
The glucose and amino acid solutions are clear and colorless or pale yellow in color. The emulsion
lipid is of a milky white appearance.
The upper and intermediate compartments can be connected to the lower compartment by opening the
intermediate seals.
The different sizes of the container are packaged in boxes containing five bags.
Packs: 5 x 1,250 ml, 5 x 1,875 ml and 5 x 2,500 ml
Not all pack sizes may be marketed.

Marketing authorisation holder and manufacturer

  • B. Braun Melsungen AG Carl-Braun-Str. 1 Postal address:34212 Melsungen, Germany 34209 Melsungen, Germany Tel.: +49-(0)-5661-71-0 Fax: +49-(0)-5661-71-4567

This medicinal product is authorised in the Member States of the European Economic Area with the following
denominations:

Austria Nutriflex Lipid peri B. Braun
Belgium Nutriflex Lipid peri, 32 g/l AA + 64 g/l G , emulsion for infusion
Bulgaria Nutriflex Lipid 32/64 peri emulsion for infusion
Czech Republic Nutriflex Lipid peri 32/64,
Denmark Lipoflex peri
Finland Nutriflex Lipid 32/64/40 peripheral
France Lipoflex Lipide G64/N4,6/E, emulsion for perfusion
Germany Nutriflex Lipid 32/64 peri
Iceland Nutriflex Lipid 32/64 peri
Italy Lipoflex, AA32/G64 emulsion for infusion
Luxembourg Nutriflex Lipid 32/64 peri
Netherlands Nutriflex Lipid peri, 32 g/l + 64 g/l,
emulsion for infusion
Norway Lipoflex peri
Poland Lipoflex peri
Romania Lipoflex peri emulsion for perfusion
Slovakia Nutriflex Lipid Peri 32/64,
Spain Nutriflex Lipid 32/64 peri emulsion for perfusion
Sweden Nutriflex Lipid 32/64 peripheral
United Kingdom Lipoflex peri emulsion for infusion
______________________________________________________________________________
The following information is intended exclusively for physicians or healthcare professionals:
No special instructions for disposal.
Before use, parenteral nutrition products must be visually inspected for any damage, colour changes and emulsion instability.
Do not use damaged bags. The outer packaging, the primary bag and the seal between the compartments must be
intact. Use only if the amino acid and glucose solutions are clear and colourless to straw-yellow and if
the lipid emulsion is homogeneous and milky white in appearance. Do not use if the solutions contain
particles.
After mixing the three compartments, do not use if the emulsion shows colour changes or signs of
phase separation (oily droplets, oily layer). Immediately stop the infusion if there is a change in colour or
signs of phase separation.
Before opening the outer packaging, check the colour of the oxygen indicator (see Figure A). Do not use if
the oxygen indicator is pink. Use only if the oxygen indicator is yellow.

Preparation of the emulsion by mixing
Strict adherence to the rules of aseptic procedure must be observed.
To open: tear the outer packaging starting from the designated notches (Fig. 1). Remove the bag from the protective
outer packaging. Discard the outer packaging, the oxygen indicator and the oxygen absorber.
Visually inspect the primary bag for any leaks. Leaking bags must be
discarded, as sterility is not guaranteed in this case.

Preparation of the

To open and gradually mix the compartments, roll the bag with both hands, pressing on the
seal separating the upper compartment (glucose) from the lower compartment (amino acids) (Fig. 2a). Continue
to press until the seal separating the intermediate compartment (lipids) from the lower compartment is opened (Fig. 2b).
After removing the aluminium closure (Fig. 3), compatible additives can be added through the
port intended for the addition of medicinal products (Fig. 4).

Hand opening a transparent plastic bag with a notch and a black arrow indicating the direction

Carefully mix the contents of the bag (Fig. 5) and visually inspect the mixture (Fig. 6). No
signs of phase separation of the emulsion should be visible.
The mixture is a homogeneous oil-in-water emulsion, milky white in appearance.

Preparation of the infusion
The emulsion must always be brought to room temperature before infusion.
Remove the aluminium film (Fig. 7) from the infusion port and connect the infusion set (Fig. 8).
Use a non-vented infusion set or close the air vent if a vented set is used. Hang the
bag on an infusion stand (Fig. 9) and perform the infusion according to standard techniques.

Hands opening a sealed bag with a notch, open bag and visible contents, bag hanging on a hook with a tear-off closure

For single use only. The container and any unused residue must be discarded after use.
Do not reconnect a partially used container.
If filters are used, they must be lipid-permeable (pore size ≥1.2 µm).

Period of validity after removal of the protective outer packaging and mixing of the bag contents
The chemical and physicochemical stability in use of the mixture of amino acids, glucose and fats has been demonstrated for
7 days at 2-8°C and for 2 additional days at 25°C.

Period of validity after addition of compatible additives
From a microbiological point of view, the product must be used immediately after the addition of additives.
If the product is not used immediately after the addition of additives, the user is responsible for the
timing and conditions of storage during use.
The emulsion must be used immediately after opening the container.
Lipoflex, AA32 /G64 must not be mixed with other medicinal products for which compatibility has not been
documented. Compatibility data for various additives (e.g. electrolytes, trace elements, vitamins) and the validity periods for these mixtures can be provided on request by the manufacturer.
Lipoflex, AA32 / G64 must not be administered simultaneously with blood in the same infusion set due to the risk of pseudoagglutination.

Duration of infusion of a single bag
The recommended infusion duration for a bag for parenteral nutrition is a maximum of 24 hours.

Lipoflex,AA38/G120 emulsion for infusion
Read this leaflet carefully before you use this medicine because it contains important
information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others, even if their symptoms are the same as yours, as it could be harmful.
  • If you get any side effects, even those not listed in this leaflet, tell your doctor, pharmacist or nurse. See section 4.

Contents of this leaflet:

  • 1. What is Lipoflex, AA38/G120 and what is it used for
  • 2. What you need to know before you use Lipoflex, AA38/G120
  • 3. How to use Lipoflex, AA38/G120
  • 4. Possible side effects
  • 5. How to store Lipoflex, AA38/G120
  • 6. Contents of the pack and other information
  • 1.What is Lipoflex,AA38/G120 and what is it used for

Lipoflex, AA38/G120 contains fluids and substances called amino acids, electrolytes and fatty acids, which are
essential for the body to grow or heal. It also contains calories in the form of carbohydrates and
fats.
Lipoflex, AA38/G120 is given to you when you are unable to feed yourself normally. Numerous
situations may require its use, for example during recovery from surgery, injuries or
burns or when you are unable to absorb food from your stomach or intestines.

  • 2.What you need to know before you use Lipoflex,AA38/G120

Do not use Lipoflex,AA38/G120

  • if you are allergic to any of the active ingredients, to eggs, peanuts, soya or any of the other ingredients of this medicine (listed in section 6).
  • This medicine must not be given to newborn infants, infants and children under two years of age.

Also, do not use Lipoflex, AA38/G120 if you suffer from any of the following conditions:

  • life-threatening circulatory problems, such as those that can occur when you are in a state of collapse or shock
  • heart attack or stroke
  • severe impairment of blood clotting, risk of bleeding (severe coagulopathy, worsening haemorrhagic diathesis)
  • blockage of blood vessels by blood clots or fat (embolism)
  • severe liver failure
  • impaired bile flow (intrahepatic cholestasis)
  • severe kidney failure without renal replacement therapy
  • imbalances in the content of salts in the body
  • lack of fluids or excess water in the body
  • water in the lungs (pulmonary oedema)
  • severe heart failure
  • certain metabolic disorders, such as
    • too many lipids (fats) in the blood
    • congenital disorders of amino acid metabolism
    • unusually high blood sugar levels that require more than 6 units of insulin per hour to keep under control
    • abnormalities in metabolism that can occur after surgery or injury
    • coma of unknown origin
    • insufficient oxygen supply to the tissues
    • abnormally high levels of acid in the blood.

Warnings and precautions
Talk to your doctor, pharmacist or nurse before you use Lipoflex, AA38/G120.
Tell your doctor if:

  • you have problems with your heart, liver or kidneys
  • you suffer from certain types of metabolic disorders such as diabetes, abnormal fat levels in the blood and imbalances in fluid and salt content in the body or alterations in acid-base balance. You will be carefully monitored to detect early signs of an allergic reaction (such as fever, chills, rash or difficulty breathing) when you receive this medicine.

Other checks and tests, such as various examinations performed on blood samples, will be carried out to verify that
your body is using the nutrients supplied correctly.
The nursing staff may also take measures to ensure that your fluid and electrolyte needs are met. In addition to Lipoflex, AA38/G120 you may receive other nutrients
(foods) to fully cover your needs.

Children
This medicine must not be given to newborn infants, infants and children under two years of age.

Other medicines and Lipoflex,AA38/G120
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take
any other medicines.
Lipoflex, AA38/G120 can interact with other medicines. Tell your doctor, pharmacist or nurse if you are
taking or are given any of the following medicines:

  • insulin
  • heparin
  • medicines that prevent unwanted blood clotting, such as warfarin or other coumarin derivatives
  • medicines that promote urine flow (diuretics)
  • medicines used to treat high blood pressure (ACE inhibitors)
  • medicines used to treat high blood pressure or heart problems (angiotensin II receptor antagonists)
  • medicines used in organ transplantation, such as cyclosporine and tacrolimus
  • medicines used to treat inflammation (corticosteroids)
  • hormonal preparations that affect fluid balance (adrenocorticotropic hormone or ACTH)

Pregnancy and breastfeeding
If you are pregnant, or suspect you may be pregnant, or are breastfeeding, ask your doctor or pharmacist for advice before taking this medicine. If you are pregnant, you will
receive this medicine only if your doctor or pharmacist considers it essential for recovery. There are
no data available on the use of Lipoflex, AA38/G120 in pregnant women.
Breastfeeding is not recommended for women receiving parenteral nutrition.

Driving and using machines
This medicine is normally given to immobilised patients, e.g. in hospital or clinic,
and this excludes the possibility of driving vehicles and operating machinery. In any case, the medicine has
no effects on the ability to drive vehicles or operate machinery.

  • 3.How to use Lipoflex,AA38/G120 This medicine is administered by intravenous infusion (drip), i.e. through a small tube inserted directly into a vein. This medicine is administered exclusively into one of the large veins (central veins).

The doctor or pharmacist will determine the amount of medicine you need and the duration of treatment with
this medicine.

Use in children
This medicine must not be given to newborn infants, infants and children under two years of age.

If you use more Lipoflex,AA38/G120 than you should
If you have received an excessive amount of this medicine, you may suffer from the so-called "overload syndrome" with the following symptoms:

  • excess fluid and electrolyte disturbances
  • fluid in the lungs (pulmonary edema)
  • loss of amino acids through the urine and disturbances of amino acid balance
  • vomiting, nausea
  • chills
  • high blood sugar levels
  • glucose in the urine
  • fluid deficiency
  • blood much more concentrated than normal (hyperosmolarity)
  • reduction or loss of consciousness due to extremely high blood sugar levels
  • enlargement of the liver (hepatomegaly) with or without jaundice
  • enlargement of the spleen (splenomegaly)
  • fat deposition in internal organs
  • abnormal values of liver function tests
  • reduction of red blood cell count in the blood (anemia)
  • reduction of white blood cell count in the blood (leukopenia)
  • reduction of platelet count in the blood (thrombocytopenia)
  • increase of immature red blood cells (reticulocytosis)
  • breakdown of blood cells (hemolysis)
  • bleeding or tendency to bleed
  • impairment of blood coagulation (characterized by alterations in bleeding time, coagulation time, prothrombin time, etc.)
  • fever
  • high levels of fats in the blood
  • loss of consciousness

If any of these symptoms occur, the infusion must be stopped immediately.
If you have any doubts about the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects may be serious. If you experience any of the following side effects, inform your doctor immediately, who will stop administering this medicine:
Rare (may affect up to 1 in 1,000 people):

  • allergic reactions, such as skin reactions, shortness of breath, swelling of the lips, mouth and throat, difficulty breathing

Other side effects include:
Uncommon (may affect up to 1 in 100 people):

  • nausea, vomiting, loss of appetite

Rare (may affect up to 1 in 1,000 people):

  • increased tendency of the blood to clot
  • bluish discoloration of the skin
  • shortness of breath
  • headache
  • hot flushes
  • redness of the skin (erythema)
  • sweating
  • shivering
  • feeling of cold
  • elevated body temperature
  • drowsiness
  • chest, back, bone or lower back pain
  • decrease or increase in blood pressure

Very rare (may affect up to 1 in 10,000 people):

  • unusually high levels of fats or sugars in the blood
  • high levels of acidic substances in the blood
  • an excess of lipids can lead to a lipid overload syndrome; for more information see “If you use more Lipoflex, AA38/G120 than you should” in section 3. Symptoms usually disappear when the infusion is stopped.

Not known (frequency cannot be estimated from the available data):

  • decreased white blood cell count (leukopenia)
  • decreased platelet count (thrombocytopenia)
  • impaired bile flow (cholestasis)

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse, including any side effects not listed in this leaflet.
You can also report side effects directly through the national reporting system at www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa”. By reporting side effects you can help provide more information on the safety of this medicine.

  • 5.How to store Lipoflex,AA38/G120

Keep this medicine out of the sight and reach of children.
Do not store above 25 °C.
Do not freeze. If accidental freezing occurs, discard the bag.
Keep the bag in the protective packaging to protect the medicine from light.
Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.

6. Package contents and other information

What Lipoflex,AA38/G120 contains,
The active ingredients contained in the ready-to-use mixture are:

from the upper compartment (glucose solution)l in 1,000 mlin 1,250 mlin 1,875 mlin 2,500 ml
Monohydrate glucose equivalent to glucosea 132.0 g 120.0 g165.0 g 150.0 g247.5 g 225.0 g330.0 g 300.0 g
Dihydrate disodium phosphatet 1.872 g2.340 g3.510 g4.680 g
I Zinc acetate dihydrate5.264 mg6.580 mg9.870 mg13.16 mg
a from the intermediate compartment (lipid emulsion)in 1,000 mlin 1,250 mlin 1,875 mlin 2,500 ml
i Refined soybean oil20.00 g25.00 g37.50 g50.00 g
Medium chain triglycerides20.00 g25.00 g37.50 g50.00 g
from the lower compartment (amino acid solution)in 1,000 mlin 1,250 mlin 1,875 mlc in 2,500 ml
Isoleucine2.256 g2.820 g4.230 g5.640 g
Leucine3.008 g3.760 g5.640 ga 7.520 g
Lysine hydrochloride equivalent to lysine2.728 g 2.184 g3.410 g 2.729 g5.115 g 4.094 g6.820 g 5.459 g
Methionine1.880 g2.350 g3.525 gm 4.700 g
Phenylalanine3.368 g4.210 g6.315 g8.420 g
Threonine1.744 g2.180 gr 3.270 g4.360 g
Tryptophan0.544 g0.680 ga 1.020 g1.360 g
Valine2.496 g3.120 g4.680 g6.240 g
Arginine2.592 g3.240 gF 4.860 g6.480 g
Histidine hydrochloride monohydrate equivalent to histidine1.624 g 1.202 g2.030 g 1.503 g3.045 g 2.255 g4.060 g 3.005 g
Alanine4.656 g5.820 gl 8.730 g11.64 g
Aspartic acid1.440 g1.800 g2.700 g3.600 g
Glutamic acid3.368 ge 4.210 g6.315 g8.420 g
Glycine1.584 g1.980 g2.970 g3.960 g
Proline3.264 gd 4.080 g6.120 g8.160 g
Serine2.880 g3.600 g5.400 g7.200 g
Sodium hydroxide0.781 g0.976 g1.464 g1.952 g
Sodium chloride0.402 ga 0.503 g0.755 g1.006 g
Sodium acetate trihydrate0.222 g0.277 g0.416 g0.554 g
Potassium acetaten 2.747 g3.434 g5.151 g6.868 g
Magnesium acetate tetrahydrate0.686 g0.858 g1.287 g1.716 g
Calcium chloride dihydratea 0.470 g0.588 g0.882 g1.176 g
Electrolytesin 1,000 mlin 1,250 mlin 1,875 mlin 2,500 ml
Sodiuma 40 mmol50 mmol75 mmol100 mmol
Potassiumt 28 mmol35 mmol52.5 mmol70 mmol
Magnesium3.2 mmol4.0 mmol6.0 mmol8.0 mmol
I Calcium3.2 mmol4.0 mmol6.0 mmol8.0 mmol
Zinc0.024 mmol0.03 mmol0.045 mmol0.06 mmol
a Chloride36 mmol45 mmol67.5 mmol90 mmol
Acetate36 mmol45 mmol67.5 mmol90 mmol
i Phosphate12 mmol15 mmol22.5 mmol30 mmol
Amino acid content38 g48 g72 g96 g
n Nitrogen content5.4 g6.8 g10.2 g13.7 g
Carbohydrate content120 g150 g225 g300 g
e Lipid content40 g50 g75 g100 g
Energy supply in the form of lipids
  • 1,590 kJ (380 kcal)
  • 1,990 kJ (475 kcal)
  • 2,985 kJ (715 kcal)
c
  • 3,980 kJ (950 kcal)
Energy supply in the form of carbohydrates
  • 2,010 kJ (480 kcal)
  • 2,510 kJ (600 kcal)
  • 3,765 kJ (900 kcal)
a
  • 5,020 kJ (1,200 kcal)
Energy supply in the form of amino acids635 kJ (150 kcal)800 kJ (190 kcal)
  • 1,200 kJ (285 kcal)
  • 1,600 kJ (380 kcal)
Non-protein energy supply
  • 3,600 kJ (860 kcal)
  • 4,500 kJ (1,075 kcal)
  • 6,750 kJ (1,615 kcal)
m
  • 9,000 kJ (2,150 kcal)
Total energy supply
  • 4,235 kJ (1,010 kcal)
  • 5,300 kJ (1,265 kcal)
r
  • 7,950 kJ (1,900 kcal)
  • 10,600 kJ (2,530 kcal)
Osmolality
  • 1,540 mOsm m/kg
  • 1,540 mOsm m/kg
F
  • 1,540 mOsm/ kg
  • 1,540 mOsm m/kg
Theoretical osmolarity
  • 1,215 mOsm m/l
  • 1,215 mOsm m/l
  • 1,215 mOsm/l l
  • 1,215 mOsm m/l
pH5.0-6.05.0-6.05.0-6.05.0-6.0

The other components are citric acid monohydrate (to adjust the pH), egg lecithin, glycerol, sodium oleate,
all-rac-alpha-tocopherol and water for injections.

Description of the appearance of Lipoflex,AA38/G120 and package contents
The ready-to-use product is an emulsion for infusion, i.e. it is administered through a tube inserted
into a vein.
Lipoflex, AA38/G120 is supplied in flexible multi-compartment bags containing:

  • 1,250 ml (500 ml of amino acid solution + 250 ml of lipid emulsion + 500 ml of glucose solution)
  • 1,875 ml (750 ml of amino acid solution + 375 ml of lipid emulsion + 750 ml of glucose solution)
  • 2,500 ml (1,000 ml of amino acid solution + 500 ml of lipid emulsion + 1,000 ml of glucose solution)
Rectangular package with oxygen indicator and oxygen absorber, tear notches and top coverInfusion bag with compartments for glucose, fats, amino acid emulsions and infusion and medication port
Packaging

Figure A Figure B
Figure A: the multi-compartment bag is wrapped in a protective packaging. Between the bag and the packaging there are an
oxygen absorber and an oxygen indicator; the oxygen absorber bag is made of inert material and
contains iron hydroxide.
Figure B: the upper compartment contains a glucose solution, the intermediate compartment contains
a lipid emulsion and the lower compartment contains an amino acid solution.
The glucose and amino acid solutions are clear and colorless or straw-yellow in color. The emulsion
lipid is milky white in appearance.
The upper and intermediate compartments can be connected to the lower compartment by opening the
intermediate seals.
The different container sizes are packaged in boxes containing five bags.
Packages: 5 x 1,250 ml, 5 x 1,875 ml and 5 x 2,500 ml
Not all packages may be marketed.

Marketing authorisation holder and manufacturer

  • B. Braun Melsungen AG Carl-Braun-Str. 1 Postal address:34212 Melsungen, Germany 34209 Melsungen, Germany Tel.: +49-(0)-5661-71-0 Fax: +49-(0)-5661-71-4567

This medicinal product is authorised in the Member States of the European Economic Area under the following
denominations:

Austria Nutriflex Lipid plus B. Braun
Belgium Nutriflex Lipid plus, 38 g/l AA + 120 g/l G, emulsion for infusion
Czech Republic Nutriflex Lipid plus 38/120
Denmark Lipoflex Plus
Finland Nutriflex Lipid 38/120/40
France LIPOFLEX LIPIDE G120/N5,4/E, emulsion for perfusion
Germany Nutriflex Lipid 38/120 plus
Iceland Nutriflex Lipid 38/120 plus
Italy Lipoflex, AA38/G120
Luxembourg Nutriflex Lipid 38/120 plus
Netherlands Nutriflex Lipid plus, 38 g/l + 120 g/l, emulsion for infusion
Norway Lipoflex plus
Poland Lipoflex plus
Romania Lipoflex plus emulsion for perfusion
Slovakia Nutriflex Lipid plus 38/120,
Spain Nutriflex Lipid 38/120 plus emulsion for perfusion
Sweden Nutriflex Lipid 38/120/40
United Kingdom Lipoflex plus emulsion for infusion
______________________________________________________________________________
The following information is intended exclusively for physicians or healthcare professionals:
No special instructions for disposal.
Before use, parenteral nutrition products must be visually inspected for any damage, colour changes and emulsion instability.
Do not use damaged bags. The wrapper, primary bag and weld between the compartments must be
intact. Use only if the amino acid and glucose solutions are clear and colourless to straw-yellow and if
the lipid emulsion is homogeneous and milky white in appearance. Do not use if the solutions contain
particles.
After mixing the three compartments, do not use if the emulsion shows colour changes or signs of
phase separation (oily droplets, oily layer). Immediately stop the infusion if there is a change in colour or
signs of phase separation.
Before opening the wrapper, check the colour of the oxygen indicator (see Figure A). Do not use if
the oxygen indicator is pink. Use only if the oxygen indicator is yellow.

Preparation of the emulsion by mixing
To open: tear the wrapper starting from the appropriate incisions (Fig. 1). Remove the bag from the protective
wrapper. Discard the wrapper, oxygen indicator and oxygen absorber.
Visually inspect the primary bag for any leaks. Leaking bags must be discarded, as sterility is not guaranteed.
After removing the aluminum closure (Fig. 3), compatible additives can be added through the
port intended for adding medications (Fig. 4).

Preparation of the

To open and gradually mix the compartments, roll the bag with both hands, pressing on the weld that separates the upper compartment (glucose) from the lower compartment (amino acids) (Fig. 2a). Continue
to press until the weld separating the intermediate compartment (lipids) from the lower compartment is opened (Fig. 2b).
Mix the contents of the bag carefully (Fig. 5) and inspect the mixture visually (Fig. 6). No
signs of phase separation of the emulsion should be visible.
The mixture is a homogeneous oil-in-water emulsion, milky white in appearance.

Preparation of the infusion
The emulsion must always be brought to room temperature before infusion.
Remove the aluminum foil (Fig. 7) from the infusion port and connect the infusion set (Fig. 8).
Use a non-vented infusion set or close the air vent if a vented set is used. Hang the
bag on an IV pole (Fig. 9) and administer the infusion according to standard techniques.

Hand opening a transparent plastic bag with a zipper, black arrow indicates the opening movement

For single use only. The container and any unused residue must be discarded after use.
Do not reconnect a partially used container.
If filters are used, they must be permeable to lipids (pore size ≥1.2 µm).

Period of validity after removal of the protective wrapper and mixing of the bag contents
The chemical and physicochemical stability in use of the mixture of amino acids, glucose and fats has been demonstrated for
7 days at 2-8°C and for 2 additional days at 25°C.

Period of validity after addition of compatible additives
From a microbiological point of view, the product must be used immediately after the addition of additives.
If the product is not used immediately after the addition of additives, the user is responsible for the
timing and conditions of storage during use.
The emulsion must be used immediately after opening the container.
Lipoflex, AA38/G120 should not be mixed with other medicinal products for which compatibility has not been
documented. Compatibility data for various additives (e.g. electrolytes, trace elements, vitamins) and the validity periods for these mixtures can be provided on request by the manufacturer.
Lipoflex, AA38/G120 should not be administered simultaneously with blood in the same infusion set due to the risk of pseudoagglutination.

Duration of infusion of a single bag
The recommended infusion duration for a bag for parenteral nutrition is a maximum of 24 hours.

Lipoflex, AA 56 / G 144without electrolytes emulsion for infusion
Read this leaflet carefully before you use this medicine because it contains important
information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others, even if their symptoms are the same as yours, as it could be harmful.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. See section 4.

Contents of this leaflet:

  • 1. What is Lipoflex, AA 56 / G 144 without electrolytes and what it is used for
  • 2. What you need to know before you use Lipoflex, AA 56 / G 144 without electrolytes
  • 3. How to use Lipoflex, AA 56 / G 144 without electrolytes
  • 4. Possible side effects
  • 5. How to store Lipoflex, AA 56 / G 144 without electrolytes
  • 6. Contents of the pack and other information

1. What is Lipoflex, AA 56 / G 144 without electrolytes and what is it for

Lipoflex, AA 56 / G 144 without electrolytes contains liquids and substances called amino acids and fatty acids, which
are essential for the body to grow or heal. It also contains calories in the form of carbohydrates and fats.
Lipoflex, AA 56 / G 144 without electrolytes is administered when you are unable to feed yourself
normally. This can happen in many situations, for example after surgery, injuries or
burns, or if you are unable to absorb food in your stomach and intestines.

2. What you need to know before using Lipoflex, AA 56 / G 144 without electrolytes

Do not use Lipoflex, AA 56 / G 144without electrolytes

  • if you are allergic to any of the active ingredients, to eggs, peanuts, soy or to any of the other components of this medicine (listed in section 6).
  • This medicine must not be administered to newborns, infants and children under two years of age.

In addition, do not use Lipoflex, AA 56 / G 144 without electrolytes if you suffer from any of the following conditions:

  • potentially life-threatening disorders of blood circulation, such as those that may occur in case of collapse or shock
  • heart attack or stroke
  • severe impairment of blood coagulation, risk of bleeding (severe coagulopathy, worsening haemorrhagic diathesis)
  • obstruction of blood vessels by blood clots or fat (embolism)
  • severe liver failure
  • impaired bile flow (intrahepatic cholestasis)
  • severe kidney failure in the absence of renal replacement therapy
  • imbalances in the salt content in the body
  • fluid deficiency or excess water in the body
  • water in the lungs (pulmonary edema)
  • severe heart failure
  • certain metabolic disorders, such as
    • too many lipids (fats) in the blood
    • congenital disorders of amino acid metabolism
    • blood sugar levels that are too high and require more than 6 units of insulin per hour to keep under control
    • metabolic abnormalities that may occur after surgery or injury
    • coma of unknown origin
    • insufficient oxygen supply to the tissues
    • too high a level of acids in the blood.

Warnings and precautions
Consult your doctor, pharmacist or nurse before using Lipoflex, AA 56 / G 144 without electrolytes.
Tell your doctor if:

  • you have problems with your heart, liver or kidneys
  • you suffer from certain types of metabolic disorders such as diabetes, abnormal blood fat levels and imbalances in fluid and salt content in the body or alterations in acid-base balance.

You will be carefully monitored for early signs of an allergic reaction (such as fever, chills,
skin rash or shortness of breath) when receiving this medicine.
Further checks and tests, such as various tests performed on blood samples, will be carried out to ensure that your
body uses the administered nutrients correctly.
This medicine is an electrolyte-free solution. The healthcare professional will take measures to ensure an
adequate supply of fluids and electrolytes to your needs. In addition to this medicine you will receive other nutrients (food) to fully cover your needs.

Children
This medicine must not be administered to newborns, infants and children under two years of age.

Other medicines and Lipoflex, AA 56 / G 144without electrolytes
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take
any other medicines.
Lipoflex, AA 56 / G 144 without electrolytes can interact with other medicines. Tell your doctor, pharmacist or
nurse if you are taking or are given any of the following medicines:

  • insulin
  • heparin
  • medicines that prevent inappropriate blood clotting, such as warfarin or other coumarin derivatives

Pregnancy and breastfeeding
If you are pregnant, suspect you are pregnant or are planning to become pregnant, or if you are breastfeeding
ask your doctor or pharmacist for advice before taking this medicine. If you are pregnant, you will
receive this medicine only if your doctor or pharmacist considers it essential for your recovery. No
data are available regarding the use of Lipoflex, AA 56 / G 144 without electrolytes in pregnant women.
Breastfeeding is not recommended for women receiving parenteral nutrition.

Driving and using machines
This medicine is normally administered to immobilized patients, e.g. in hospital or
clinic, who therefore do not drive or operate machinery. In any case, the medicine has no effects
on the ability to drive vehicles or operate machinery.
Lipoflex, AA 56 / G 144 without electrolytes contains sodium

This medicine contains less than 1 mmol (23 mg) of sodium per multi-compartment bag, i.e. it is practically
“sodium-free”.

3. How to use Lipoflex, AA 56 / G 144 without electrolytes

This medicine is administered via intravenous infusion (drip), i.e. through a small tube
inserted directly into a vein. The medicine is administered exclusively into one of the large veins
(central veins).

The doctor or pharmacist will determine the amount of medicine you need and the duration of treatment with
this medicine.

Use in children
This medicine should not be administered to newborns, infants and children under two years of age.

If you use more Lipoflex, AA 56 / G 144 without electrolytes than you should
If you have received an excessive amount of this medicine, you may suffer from the so-called “overload
syndrome” with the following symptoms:

  • excess fluid and electrolyte disturbances
  • fluid in the lungs (pulmonary edema)
  • loss of amino acids in the urine and disturbances in amino acid balance
  • vomiting, nausea
  • shivering
  • high blood sugar levels
  • glucose in the urine
  • fluid deficit
  • excessive blood concentration (hyperosmolarity)
  • reduction or loss of consciousness due to extremely high blood sugar levels
  • enlargement of the liver (hepatomegaly) with or without jaundice
  • enlargement of the spleen (splenomegaly)
  • fat deposition in internal organs
  • alterations in liver function parameters
  • reduction in the number of red blood cells in the blood (anemia)
  • reduction in the number of white blood cells in the blood (leukopenia)
  • low platelet count in the blood (thrombocytopenia)
  • increase in immature red blood cells (reticulocytosis)
  • breakdown of blood cells (hemolysis)
  • bleeding or tendency to bleed
  • blood clotting disorders (characterized by alterations in bleeding time, coagulation time, prothrombin time, etc.)
  • fever
  • high levels of fats in the blood
  • loss of consciousness If any of these symptoms occur, the infusion must be stopped immediately.

If you have any questions about the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
manifest.

The following side effects may be serious. If you experience any of the following side effects,
inform your doctor immediately, who will stop administering this medicine:

Rare (may affect up to 1 in 1,000 people):

  • allergic reactions, such as skin reactions, shortness of breath, swelling of the lips, mouth and throat, difficulty breathing

Other side effects include:
Uncommon (may affect up to 1 in 100 people):

  • nausea, vomiting, loss of appetite

Rare (may affect up to 1 in 1,000 people):

  • increased tendency of the blood to clot
  • bluish discoloration of the skin
  • shortness of breath
  • headache
  • hot flushes
  • redness of the skin (erythema)
  • sweating
  • shivering
  • feeling of cold
  • elevated body temperature
  • drowsiness
  • chest, back, bone or lower back pain
  • decrease or increase in blood pressure

Very rare (may affect up to 1 in 10,000 people):

  • excessive levels of fats or sugars in the blood
  • high levels of acidic substances in the blood
  • an excess of lipids can lead to a lipid overload syndrome; for more information see “If you use more Lipoflex, AA 56 / G 144 without electrolytes than you should” in section 3. Symptoms usually disappear with discontinuation of the infusion.

Not known (frequency cannot be estimated from available data):

  • decreased white blood cell count (leukopenia)
  • decreased platelet count in the blood (thrombocytopenia)
  • impaired bile flow (cholestasis)

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse.
You can also report side effects directly through the national reporting system
at www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa”. By reporting
side effects you can help provide more information on the safety of this medicine.

5. How to store Lipoflex, AA 56 / G 144 without electrolytes

Keep this medicine out of the sight and reach of children.
Do not store at a temperature above 25 °C.
Do not freeze. If accidental freezing occurs, discard the bag.
Keep the bag in the protective packaging to protect the medicine from light.
Do not use this medicine after the expiry date which is stated on the label. The expiry date refers
to the last day of that month.

6. Contents of the pack and other information

What Lipoflex, AA 56 / G 144 without electrolytes contains
The active ingredients contained in the ready-to-use mixture are:

a from the upper compartment i (glucose solution)in 1,000 mlin 625 mlin 1,250 mlin 1,875 ml
z Glucose monohydrate equivalent to glucose158.4 g 144.0 g99.00 g 90.00 g198.0 g 180.0 g297.0 g 270.0 g
n from the intermediate compartment (lipid emulsion)in 1,000 mlin 625 mlin 1,250 mlin 1,875 ml
e Refined soybean oil20.00 g12.50 g25.00 g37.50 g
Medium chain triglycerides20.00 g12.50 g25.00 g37.50 g
from the lower compartment (amino acid solution)in 1,000 mlin 625 mlin 1,250 mlc in 1,875 ml
Isoleucine3.284 g2.053 g4.105 g6.158 g
Leucine4.384 g2.740 g5.480 ga 8.220 g
Lysine monohydrate equivalent to lysine3.576 g 3.184 g2.235 g 1.990 g4.470 g 3.979 g6.705 g 5.969 g
Methionine2.736 g1.710 g3.420 gm 5.130 g
Phenylalanine4.916 g3.073 g6.145 g9.218 g
Threonine2.540 g1.588 gr 3.175 g4.763 g
Tryptophan0.800 g0.500 ga 1.000 g1.500 g
Valine3.604 g2.253 g4.505 g6.758 g
Arginine3.780 g2.363 gF 4.725 g7.088 g
Histidine1.752 g1.095 g2.190 g3.285 g
Alanine6.792 g4.245 g8.490 g12.73 g
Aspartic acid2.100 g1.313 gl 2.625 g3.938 g
Glutamic acid4.908 g3.068 g6.135 g9.203 g
Glycine2.312 ge 1.445 g2.890 g4.335 g
Proline4.760 g2.975 g5.950 g8.925 g
Serine4.200 gd 2.625 g5.250 g7.875 g
in 1,000 mlin 625 mlin 1,250 mlin 1,875 ml
Amino acid content56.0 ga 35.0 g70.1 g105.1 g
Nitrogen content8 g5 g10 g15 g
Carbohydrate contentn 144 g90 g180 g270 g
Lipid contenta 40 g25 g50 g75 g
Energy supply in the form of lipidsi l
  • 1,590 kJ (380 kcal)
995 kJ (240 kcal)
  • 1,990 kJ (475 kcal)
  • 2,985 kJ (715 kcal)
Energy supply in the form of carbohydratesa
  • 2,415 kJ (575 kcal)
  • 1,510 kJ (360 kcal)
  • 3,015 kJ (720 kcal)
  • 4,520 kJ (1,080 kcal)
Energy supply in the form of amino acidst 940 kJ (225 kcal)585 kJ (140 kcal)
  • 1,170 kJ (280 kcal)
  • 1,755 kJ (420 kcal)
I Non-protein energy supply
  • 4,005 kJ (955 kcal)
  • 2,505 kJ (600 kcal)
  • 5,005 kJ (1,195 kcal)
  • 7,505 kJ (1,795 kcal)
a Total energy supply
  • 4,945 kJ (1,180 kcal)
  • 3,090 kJ (740 kcal)
  • 6,175 kJ (1,475 kcal)
  • 9,260 kJ (2,215 kcal)

The other components are citric acid monohydrate (to adjust the pH), egg lecithin, glycerol, sodium oleate,
all-rac-alpha-tocopherol and water for injections.

Description of the appearance of Lipoflex, AA 56 / G 144without electrolytes and contents of the pack

z Osmolality
  • 1,840 mOsm/kg
  • 1,840 mOsm/kg
  • 1,840 mOsm/kg
  • 1,840 mOsm/kg
n Theoretical osmolarity
  • 1,330 mOsm/l
  • 1,330 mOsm/l
  • 1,330 mOsm/l
  • 1,330 mOsm/l
e pH5.0-6.05.0-6.05.0-6.05.0-6.0

The ready-to-use product is an emulsion for infusion, i.e. it is administered through a tube inserted
into a vein.
Lipoflex, AA 56 / G 144 without electrolytes is supplied in flexible multi-compartment bags containing:

  • 625 ml (250 ml of amino acid solution + 125 ml of lipid emulsion + 250 ml of glucose solution)
  • 1,250 ml (500 ml of amino acid solution + 250 ml of lipid emulsion + 500 ml of glucose solution)
  • 1,875 ml (750 ml of amino acid solution + 375 ml of lipid emulsion + 750 ml of glucose solution)
Rectangular package with notches for openingInfusion bag divided into compartments labeled with glucose, fats, emulsion and amino acid solution with an infusion port and medication
Packaging

Figure A Figure B
Figure A: the multi-compartment bag is wrapped in a protective wrapper. Between the bag and the wrapper are a
oxygen absorber and an oxygen indicator; the oxygen absorber bag is made of inert material and
contains iron hydroxide.
Figure B: the upper compartment contains a glucose solution, the intermediate compartment contains
a lipid emulsion and the lower compartment contains an amino acid solution.
The glucose and amino acid solutions are clear and colorless or pale yellow in color. The emulsion
lipid is milky white in appearance.
The upper and intermediate compartments can be connected to the lower compartment by opening the
intermediate seals.
The different sizes of the container are packaged in boxes containing five bags.
Packages: 5 x 625 ml, 5 x 1,250 ml and 5 x 1,875 ml
Not all packs may be marketed.

Marketing authorisation holder and manufacturer

  • B. Braun Melsungen AG Carl-Braun-Str. 1 Postal address:34212 Melsungen, Germany 34209 Melsungen, Germany

Tel.: +49-(0)-5661-71-0
Fax: +49-(0)-5661-71-4567

This medicinal product is authorised in the Member States of the European Economic Area with the following
denominations:

Austria Nutriflex Lipid special ohne Elektrolyte B.Braun
Belgium Nutriflex Lipid special EF, 56 g/l AA + 144 g/l G, emulsion for infusion
France Lipoflex Lipide G144/N8, emulsion for perfusion
Germany Nutriflex Lipid 56/144 special ohne Elektrolyte
Italy Lipoflex, AA 56 / G 144 without electrolytes
Luxembourg Nutriflex Lipid 56/144 special ohne Elektrolyte
Netherlands Nutriflex Lipid pecial without electrolytes, 56 g/l + 144 g/l, emulsion for infusion
Spain Nutriflex Lipid 56/144 special without electrolytes emulsion for perfusion
United Kingdom Lipoflex special without electrolytes emulsion for infusion
______________________________________________________________________________
The following information is intended exclusively for physicians or healthcare professionals:
No special instructions for disposal.
Before use, parenteral nutrition products must be visually inspected for any damage, color changes and emulsion instability.
Do not use damaged bags. The wrapper, the primary bag and the weld between the compartments must be
intact. Use only if the amino acid and glucose solutions are clear and colorless to pale yellow and if
the lipid emulsion is homogeneous and milky white in appearance. Do not use if the solutions contain
particles.
After mixing the three compartments, do not use if the emulsion shows color changes or signs of
phase separation (oily droplets, oily layer). Immediately discontinue the infusion if
color changes or signs of phase separation occur.
Before opening the wrapper, check the color of the oxygen indicator (see Figure A). Do not use if
the oxygen indicator is pink. Use only if the oxygen indicator is yellow.

Preparation of the emulsion by mixing
Strict adherence to the rules for aseptic procedures is required.
To open: tear the wrapper starting from the appropriate incisions (Fig. 1). Remove the bag from the protective wrapper.
Discard the wrapper, oxygen indicator and oxygen absorber.
Visually inspect the primary bag for any leaks. Leaking bags must be
discarded, as sterility is not guaranteed in this case.

Hands with gloves opening and emptying a powder medicine sachet, arrows indicate the opening and emptying movement

To open and gradually mix the compartments, roll the bag with both hands, pressing on the
weld separating the upper compartment (glucose) from the lower compartment (amino acids) (Fig. 2a). Then
continue to press to open the weld separating the intermediate compartment (lipids) from the compartment
lower (Fig. 2b).
After removing the aluminum closure (Fig. 3), compatible additives can be added through the
port for adding medications (Fig. 4).

Preparation of the injection site with disinfectant wipes following the numbered instructions from 4 to 6

Carefully mix the contents of the bag (Fig. 5) and visually inspect the mixture (Fig. 6). No
signs of phase separation of the emulsion should be visible.
The mixture is a homogeneous oil-in-water emulsion, milky white in appearance.

Preparation of the infusion
The emulsion must always be brought to room temperature before infusion.
Remove the aluminum foil (Fig. 7) from the infusion port and connect the infusion set (Fig. 8).
Use a non-vented infusion set or close the air vent if a vented set is used. Hang the
bag on an infusion pole (Fig. 9) and perform the infusion according to standard techniques.

Three stages of preparation and application of a medicated patch with a visible collection bag and hands placing it

For single use only. The container and any unused residue must be discarded after use.
Do not reconnect a partially used container.
If filters are used, they must be permeable to lipids (pore size ≥1.2 µm).

Period of validity after removal of the protective wrapper and mixing of the bag contents
The chemical and physicochemical stability in use of the mixture of amino acids, glucose and fats has been demonstrated for
7 days at 2-8°C and for 2 additional days at 25°C.

Period of validity after addition of compatible additives
From a microbiological point of view, the product must be used immediately after the addition of additives.
If the product is not used immediately after the addition of additives, the user is responsible for the
timing and conditions of storage during use.
The emulsion must be used immediately after opening the container.
Lipoflex, AA 56 / G 144 without electrolytes must not be administered simultaneously with blood in the
same infusion set due to the risk of pseudoagglutination.

Duration of infusion of a single bag
The recommended infusion time for a bag for parenteral nutrition is a maximum of 24 hours.

Odpowiedniki LIPOFLEX w innych krajach

Leki z tą samą substancją czynną dostępne w innych krajach.

Odpowiednik LIPOFLEX w Hiszpania

Postać farmaceutyczna: ROZTWÓR DO WSTRZYKIWAŃ DO INFUZJI, -
Substancja czynna: combinations
Wymaga recepty
Postać farmaceutyczna: ROZTWÓR DO WSTRZYKIWAŃ DO INFUZJI, -
Substancja czynna: combinations
Producent: Baxter S.L.
Wymaga recepty
Postać farmaceutyczna: ROZTWÓR DO WSTRZYKIWAŃ DO INFUZJI, -
Substancja czynna: combinations
Producent: Baxter S.L.
Wymaga recepty
Postać farmaceutyczna: ROZTWÓR DO WSTRZYKIWAŃ DO INFUZJI, -
Substancja czynna: combinations
Producent: Baxter S.L.
Wymaga recepty
Postać farmaceutyczna: ROZTWÓR DO WSTRZYKIWAŃ DO INFUZJI, -
Substancja czynna: combinations
Wymaga recepty
Postać farmaceutyczna: ROZTWÓR DO WSTRZYKIWAŃ DO INFUZJI, Kombinacje
Substancja czynna: combinations
Wymaga recepty

Odpowiednik LIPOFLEX w Polska

Postać farmaceutyczna: Emulsja, -
Substancja czynna: combinations
Producent: Fresenius Kabi AB
Wymaga recepty
Postać farmaceutyczna: Emulsja, -
Substancja czynna: combinations
Producent: Baxter S.A.
Wymaga recepty
Postać farmaceutyczna: Emulsja, -
Substancja czynna: combinations
Importer: Baxter S.A.
Wymaga recepty
Postać farmaceutyczna: Emulsja, -
Substancja czynna: combinations
Importer: Baxter S.A.
Wymaga recepty
Postać farmaceutyczna: Emulsja, -
Substancja czynna: combinations
Producent: Fresenius Kabi AB
Wymaga recepty
Postać farmaceutyczna: Emulsja, -
Substancja czynna: combinations
Wymaga recepty

Odpowiednik LIPOFLEX w Ukraina

Postać farmaceutyczna: emulsion, 986 ml
Substancja czynna: combinations
Producent: Frezenius Kabi AB
Wymaga recepty
Postać farmaceutyczna: emulsion, 1206 ml, 1448 ml, 1904 ml
Substancja czynna: combinations
Producent: Frezenius Kabi AB
Wymaga recepty
Postać farmaceutyczna: emulsion, 1000 ml in a bag
Substancja czynna: combinations
Postać farmaceutyczna: emulsion, 1000 ml in a bag
Substancja czynna: combinations
Postać farmaceutyczna: emulsion, 1000 ml in a bag
Substancja czynna: combinations
Postać farmaceutyczna: emulsion, 625 ml, 1250 ml, 1875 ml
Substancja czynna: combinations
Wymaga recepty

Lekarze online w sprawie LIPOFLEX

Omów stosowanie LIPOFLEX, bezpieczeństwo i ocenę zasadności recepty zgodnie z obowiązującymi przepisami.

Lekarz
5.0(36)

Andrei Popov

Medycyna ogólnaMedycyna bólu7 lat doświadczenia

Dr Andrei Popov jest lekarzem rodzinnym ze specjalistycznym przygotowaniem w zakresie leczenia bólu przewlekłego. Prowadzi konsultacje wideo dla dorosłych w Hiszpanii i w całej Europie: zarówno jeśli od miesięcy zmagasz się z bólem, którego nikt nie potrafił dobrze wyjaśnić, jak i wtedy, gdy potrzebujesz rozwiązać problem zdrowotny bez czekania tygodniami na wizytę.

Jego podejście jest jasne: wysłuchać, uporządkować Twój przypadek i przedstawić praktyczny plan działania oparty na medycynie opartej na dowodach oraz dostosowany do Twojej historii medycznej i potrzeb.

Ból: w czym może pomóc

  •   Ból przewlekły (ponad 3 miesiące)
  •   Migrena i nawracające lub bardzo silne bóle głowy
  •   Ból szyi, odcinka lędźwiowego, pleców i stawów
  •   Ból pourazowy po urazach lub operacjach
  •   Ból pochodzenia neurologicznego: neuralgia, ból neuropatyczny, fibromialgia

Medycyna ogólna

  •   Częste infekcje dróg oddechowych (przeziębienie, grypa, uporczywy kaszel)
  •   Nadciśnienie, cukrzyca i zaburzenia metaboliczne
  •   Omówienie wyników badań laboratoryjnych oraz raportów MRI/CT (wyjaśnione prostym językiem)
  •   Medycyna profilaktyczna i monitorowanie zdrowia
  •   Druga opinia oraz dostosowanie leczenia (jeśli jest to klinicznie uzasadnione)

Jak wygląda konsultacja
 Każda sesja trwa do 30 minut. Omawiane są objawy, historia choroby, przyjmowane leki oraz dostarczone badania. Na zakończenie otrzymujesz jasny plan leczenia, kolejne kroki oraz wskazówki, kiedy warto zaplanować dalszą kontrolę. Jeśli zostaną wykryte sygnały alarmowe, lekarz jasno poinformuje, czy konieczna jest wizyta osobista lub pilna pomoc medyczna.

Umów wideokonsultację
zł365
Lekarz
5.0(12)

Yevgen Yakovenko

Medycyna rodzinna12 lat doświadczenia

Lek. Yevgen Yakovenko jest licencjonowanym chirurgiem i lekarzem medycyny ogólnej w Hiszpanii i Niemczech. Specjalizuje się w chirurgii ogólnej, dziecięcej i onkologicznej, a także w internie i leczeniu bólu. Prowadzi konsultacje online dla dorosłych i dzieci, łącząc precyzję chirurgiczną z kompleksowym wsparciem terapeutycznym. Konsultuje pacjentów w językach: ukraińskim, rosyjskim, angielskim i hiszpańskim.

Zakres konsultacji obejmuje:

  • Bóle ostre i przewlekłe: bóle głowy, mięśni, stawów, kręgosłupa, brzucha, bóle pooperacyjne. Identyfikacja przyczyn, dobór terapii, plan opieki.
  • Medycyna wewnętrzna: serce, płuca, układ pokarmowy, układ moczowy. Leczenie chorób przewlekłych, kontrola objawów, drugie opinie.
  • Opieka przed- i pooperacyjna: ocena ryzyka, wsparcie w podejmowaniu decyzji, kontrola po zabiegu, strategie rehabilitacyjne.
  • Chirurgia ogólna i dziecięca: przepukliny, zapalenie wyrostka robaczkowego, wady wrodzone, zabiegi planowe i pilne.
  • Urazy i kontuzje: stłuczenia, złamania, skręcenia, uszkodzenia tkanek miękkich, leczenie ran, opatrunki, skierowania do leczenia stacjonarnego.
  • Chirurgia onkologiczna: weryfikacja diagnozy, planowanie terapii, długoterminowa opieka pooperacyjna.
  • Leczenie otyłości i kontrola masy ciała: medyczne podejście do redukcji wagi, ocena chorób towarzyszących, indywidualny plan (dieta, aktywność fizyczna, farmakoterapia), monitorowanie postępów.
  • Interpretacja badań obrazowych: analiza wyników USG, TK, MRI i RTG, planowanie zabiegów chirurgicznych na podstawie danych obrazowych.
  • Drugie opinie i nawigacja medyczna: wyjaśnianie diagnoz, przegląd planów leczenia, pomoc w wyborze najlepszego postępowania.
Doświadczenie i kwalifikacje:
  • Ponad 12 lat praktyki klinicznej w szpitalach uniwersyteckich w Niemczech i Hiszpanii
  • Wykształcenie międzynarodowe: Ukraina – Niemcy – Hiszpania
  • Członek Niemieckiego Towarzystwa Chirurgów (BDC)
  • Certyfikaty z diagnostyki radiologicznej i chirurgii robotycznej
  • Aktywny uczestnik międzynarodowych konferencji i badań naukowych
Lek. Yakovenko tłumaczy złożone zagadnienia w prosty i zrozumiały sposób. Współpracuje z pacjentami, aby analizować problemy zdrowotne i podejmować decyzje oparte na dowodach naukowych. Jego podejście łączy wysoką jakość kliniczną, rzetelność naukową i indywidualne podejście do każdego pacjenta.

Jeśli nie jesteś pewien diagnozy, przygotowujesz się do operacji lub chcesz omówić wyniki badań – Lek. Yakovenko pomoże Ci ocenić opcje i podjąć świadomą decyzję.

Umów wideokonsultację
zł307
Lekarz
5.0(3)

Lina Travkina

Medycyna rodzinna13 lat doświadczenia

Lek. Lina Travkina jest licencjonowanym lekarzem medycyny rodzinnej i profilaktycznej we Włoszech. Prowadzi konsultacje online dla dorosłych i dzieci, wspierając pacjentów na każdym etapie opieki – od leczenia objawów ostrych po długoterminowe monitorowanie zdrowia i działania profilaktyczne.

Obszary opieki medycznej obejmują:

  • Choroby układu oddechowego: przeziębienia, grypa, ostre i przewlekłe zapalenie oskrzeli, lekkie i umiarkowane zapalenie płuc, astma oskrzelowa
  • Problemy laryngologiczne i okulistyczne: zapalenie zatok, migdałków, gardła, ucha środkowego, zapalenie spojówek infekcyjne i alergiczne
  • Dolegliwości ze strony układu pokarmowego: zapalenie żołądka, refluks (GERD), zespół jelita drażliwego (IBS), niestrawność, wzdęcia, zaparcia, biegunki, infekcje jelitowe
  • Choroby urologiczne i zakaźne: ostre i nawracające zapalenie pęcherza, infekcje pęcherza i nerek, profilaktyka nawracających ZUM, bezobjawowa bakteriuria
  • Choroby przewlekłe: nadciśnienie, cukrzyca, hipercholesterolemia, zespół metaboliczny, zaburzenia tarczycy, nadwaga
  • Objawy neurologiczne i ogólne: bóle głowy, migrena, zawroty, przewlekłe zmęczenie, zaburzenia snu, spadek koncentracji, lęki, astenia
  • Wsparcie w leczeniu bólu przewlekłego: bóle pleców, karku, stawów, mięśni, zespoły napięciowe, bóle związane z osteochondrozą i innymi chorobami przewlekłymi
Dodatkowe obszary opieki:
  • Konsultacje profilaktyczne i planowanie badań kontrolnych
  • Porady medyczne i wizyty kontrolne
  • Interpretacja badań i wskazówki diagnostyczne
  • Strukturalne wsparcie w przypadku niejasnych dolegliwości
  • Druga opinia w sprawie diagnozy i planu leczenia
  • Wsparcie dietetyczne i stylu życia przy niedoborach witamin, anemii, zaburzeniach metabolicznych
  • Opieka pooperacyjna i leczenie bólu
  • Konsultacje przedkoncepcyjne i wsparcie poporodowe
  • Wzmacnianie odporności i strategie redukcji częstotliwości infekcji
Lek. Travkina łączy medycynę opartą na dowodach z uważnym, spersonalizowanym podejściem. Jej konsultacje koncentrują się nie tylko na leczeniu, ale także na profilaktyce, powrocie do zdrowia i długoterminowym dobrostanie.

Jeśli w trakcie konsultacji okaże się, że Twój przypadek wymaga osobistego badania lub specjalistycznej opieki poza jej zakresem, sesja zostanie zakończona, a opłata w pełni zwrócona.

Umów wideokonsultację
zł295
Lekarz
5.0(2)

Dmytro Horobets

Medycyna rodzinnaEndokrynologia7 lat doświadczenia

Lek. Dmytro Horobets jest licencjonowanym lekarzem rodzinnym w Polsce, specjalizującym się w endokrynologii, diabetologii, leczeniu otyłości, gastroenterologii, pediatrii, chirurgii ogólnej oraz terapii bólu. Prowadzi konsultacje online dla dorosłych i dzieci, oferując spersonalizowane wsparcie medyczne w przypadku szerokiego zakresu chorób ostrych i przewlekłych.

Obszary specjalizacji obejmują:

  • Endokrynologia: cukrzyca typu 1 i 2, stan przedcukrzycowy, choroby tarczycy, zespół metaboliczny, zaburzenia hormonalne
  • Leczenie otyłości: indywidualne plany redukcji masy ciała, porady żywieniowe, ocena ryzyka zdrowotnego związanego z otyłością
  • Gastroenterologia: refluks żołądkowo-przełykowy (GERD), zapalenie żołądka, zespół jelita drażliwego (IBS), choroby wątroby i dróg żółciowych
  • Opieka pediatryczna: infekcje, objawy ze strony układu oddechowego, dolegliwości trawienne, monitorowanie rozwoju i wzrastania
  • Wsparcie chirurgiczne: konsultacje przed- i pooperacyjne, opieka nad ranami, rehabilitacja
  • Terapia bólu: ból przewlekły i ostry, bóle kręgosłupa, stawów, zespoły bólowe pourazowe
  • Zdrowie sercowo-naczyniowe: nadciśnienie, kontrola cholesterolu, ocena ryzyka chorób serca
  • Medycyna profilaktyczna: badania kontrolne, profilaktyczne, długoterminowe prowadzenie chorób przewlekłych
Lek. Horobets łączy praktykę opartą na dowodach z podejściem skoncentrowanym na pacjencie. Dokładnie analizuje historię choroby i objawy, zapewniając jasne wyjaśnienia i strukturalne plany leczenia dostosowane do indywidualnych potrzeb.

Niezależnie od tego, czy potrzebujesz wsparcia w kontroli cukrzycy, radzeniu sobie z otyłością, interpretacji wyników badań, czy opieki rodzinnej – dr Horobets zapewnia profesjonalną pomoc online, dostosowaną do Twoich celów zdrowotnych.

Umów wideokonsultację
zł302
Lekarz
5.0(19)

Nuno Tavares Lopes

Medycyna rodzinnaMedycyna ogólna18 lat doświadczenia

Lek. Nuno Tavares Lopes jest licencjonowanym lekarzem w Portugalii z 17-letnim doświadczeniem w medycynie ratunkowej, medycynie rodzinnej, praktyce ogólnej i zdrowiu publicznym. Pełni funkcję Dyrektora ds. Medycznych i Zdrowia Publicznego w międzynarodowej sieci medycznej oraz jest zewnętrznym konsultantem WHO i ECDC.

Zakres konsultacji obejmuje:

  • Opiekę doraźną: infekcje, gorączka, ból w klatce piersiowej lub brzuchu, drobne urazy, nagłe przypadki pediatryczne
  • Medycynę rodzinną: nadciśnienie, cukrzyca, wysoki cholesterol, opieka nad chorobami przewlekłymi
  • Medycynę podróży: porady przedwyjazdowe, szczepienia, zaświadczenia fit-to-fly, choroby związane z podróżą
  • Zdrowie seksualne i reprodukcyjne: PrEP, profilaktyka STD, konsultacje, leczenie
  • Kontrolę masy ciała i zdrowy styl życia: indywidualne programy odchudzania, porady dotyczące stylu życia
  • Problemy dermatologiczne i laryngologiczne: trądzik, egzema, alergie, wysypki, ból gardła, zapalenie zatok
  • Leczenie bólu: ból ostry i przewlekły, opieka pooperacyjna
  • Zdrowie publiczne: profilaktyka, badania przesiewowe, monitorowanie długoterminowe
  • Zwolnienia lekarskie (Baixa médica) powiązane z Segurança Social w Portugalii
  • Zaświadczenia medyczne IMT potrzebne do wymiany prawa jazdy
Lek. Nuno Tavares Lopes zapewnia opiekę medyczną pacjentom stosującym leki z grupy GLP-1 (Mounjaro, Wegovy, Ozempic, Rybelsus) w ramach leczenia nadwagi lub otyłości. Oferuje indywidualny plan terapii, regularne wizyty kontrolne, dostosowanie dawek oraz zalecenia dotyczące łączenia leczenia z trwałymi zmianami stylu życia. Konsultacje odbywają się zgodnie z europejskimi standardami medycznymi.

Lek. Lopes zajmuje się również interpretacją badań diagnostycznych, opieką nad pacjentami złożonymi oraz zapewnia wsparcie wielojęzyczne. Niezależnie od tego, czy chodzi o nagłe problemy zdrowotne, czy długoterminową opiekę, pomaga pacjentom działać z pewnością i spokojem.

Umów wideokonsultację
zł297
Lekarz
0.0(0)

Antonio Cayatte

Medycyna ogólna44 lat doświadczenia

Dr Antonio Cayatte to lekarz medycyny ogólnej i ostrej z ponad 30-letnim doświadczeniem klinicznym, naukowym i dydaktycznym. Prowadzi konsultacje online dla dorosłych pacjentów z ostrymi objawami lub chorobami przewlekłymi, wymagającymi kompleksowej opieki. Najczęstsze powody konsultacji: 

  • nagłe lub niejasne objawy wymagające szybkiej oceny
  • kontrola i leczenie chorób przewlekłych
  • opieka po hospitalizacji i analiza wyników badań
  • wsparcie medyczne podczas pobytu za granicą

Ukończył studia medyczne na Uniwersytecie Lizbońskim, przez wiele lat wykładał medycynę wewnętrzną na Boston University School of Medicine. Posiada aktywne prawo do wykonywania zawodu lekarza w Portugalii i Wielkiej Brytanii. Jest członkiem American Heart Association. Konsultacje odbywają się w języku angielskim lub portugalskim. Pacjenci cenią jego doświadczenie, rzeczowość i indywidualne podejście do każdej sytuacji.

Dr Antonio Cayatte zapewnia kompleksową opiekę w szerokim zakresie powszechnych problemów zdrowotnych, w tym:

  • Układ oddechowy i laryngologia: ostre zapalenie oskrzeli, stany związane z zapaleniem płuc, zapalenie zatok, zapalenie migdałków, infekcje ucha, choroby gardła, alergiczny nieżyt nosa
  •  Zdrowie oczu: alergiczne i infekcyjne zapalenie spojówek, a także zaczerwienione lub podrażnione oczy
  •  Układ pokarmowy i moczowy: choroba refluksowa przełyku (GERD), zapalenie żołądka, zakażenia dróg moczowych, zapalenie pęcherza
  •  Choroby przewlekłe: nadciśnienie tętnicze, podwyższony cholesterol oraz uporządkowane planowanie kontroli masy ciała
Umów wideokonsultację
zł323

Uzyskaj receptę na LIPOFLEX online

1

Wypełnij 2-minutowy formularz

Opisz swoje objawy, historię choroby i lek, o który prosisz.

2

Wybierz lekarza lub pozwól nam przydzielić

Wybierz specjalistę lub dopasujemy Cię do najbliższego dostępnego lekarza.

3

Lekarz analizuje Twój przypadek

Zazwyczaj w ciągu 30 minut. Może zadawać dodatkowe pytania przez czat.

4

Odbierz w dowolnej aptece

Recepta elektroniczna wysłana na Twój e-mail — ważna w całej Polsce.

Często zadawane pytania

Czy LIPOFLEX wymaga recepty?

LIPOFLEX wymaga recepty w Włochy. Możesz skonsultować się z lekarzem online, aby sprawdzić, czy ten lek może być odpowiedni w Twojej sytuacji.

Jaka jest substancja czynna w LIPOFLEX?

Substancją czynną w LIPOFLEX jest combinations. Informacja ta pomaga rozpoznać leki o tym samym składzie, ale pod różnymi nazwami handlowymi.

Kto produkuje LIPOFLEX?

LIPOFLEX jest produkowany przez B. BRAUN MELSUNGEN AG. Nazwy handlowe i opakowania mogą się różnić w zależności od dystrybutora.

Którzy lekarze mogą ocenić stosowanie LIPOFLEX online?

Lekarze, tacy jak Lekarze rodzinni, Psychiatrzy, Dermatolodzy, Kardiolodzy, Endokrynolodzy, Gastroenterolodzy, Pulmonolodzy, Nefrolodzy, Reumatolodzy, Hematolodzy, Zakaźnicy, Alergolodzy, Geriatrzy, Pediatrzy, Onkolodzy, mogą ocenić, czy stosowanie LIPOFLEX jest odpowiednie w Twoim przypadku, w zależności od sytuacji klinicznej i lokalnych przepisów. Możesz umówić konsultację online, aby omówić objawy i możliwe dalsze kroki.

Jak kupić LIPOFLEX w Polsce?

Polska posiada dobrze rozwiniętą infrastrukturę ochrony zdrowia w dużych miastach, takich jak Warszawa, Kraków, Wrocław i Gdańsk. Apteki są łatwo dostępne i działają zgodnie z obowiązującymi przepisami, zapewniając dostęp do leków na receptę.

Możesz kupić LIPOFLEX w Warszawie, Krakowie, Wrocławiu lub Gdańsku w każdej aptece, posiadając ważną receptę.

Aby uzyskać receptę, możesz skorzystać z Oladoctor:

Jakie są alternatywy dla LIPOFLEX?

Inne leki zawierające tę samą substancję czynną (combinations) to m.in. AMIXAL, BASALFLEX, KLINIMIX. Mogą one różnić się nazwą handlową lub postacią, ale zawierają ten sam składnik terapeutyczny. Przed zmianą lub rozpoczęciem nowego leku skonsultuj się z lekarzem.

Bądź na bieżąco z Oladoctor

Informacje o nowych usługach, aktualizacjach produktu i przydatnych materiałach dla pacjentów.